

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau
SCIENCE REFERENCE AND INFORMATION SERVICE



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification n ⁴ : C12Q 1/68, G01N 33/553 C02F 1/48	A1	(11) International Publication Number: WO 89/ 04373 (43) International Publication Date: 18 May 1989 (18.05.89)
--	----	--

(21) International Application Number: PCT/US88/03666

(22) International Filing Date: 18 October 1988 (18.10.88)

(31) Priority Application Number: 113,294

(32) Priority Date: 26 October 1987 (26.10.87)

(33) Priority Country: US

(71) Applicant: BAXTER INTERNATIONAL INC. [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US).

(72) Inventors: WANG, Chao-Huei, J. ; 5040 Fox Lane, Gurnee, IL 60031 (US). SHAH, Dinesh, O. ; 235 Alexandria Drive, Vernon Hills, IL 60061 (US).

(74) Agents: FENTRESS, Susan, Bennett et al.; One Baxter Parkway, Deerfield, IL 60015 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PROCESS FOR PRODUCING MAGNETICALLY RESPONSIVE POLYMER PARTICLES AND APPLICATION THEREOF

(57) Abstract

This invention provides a novel process of producing magnetically responsive polymer particles comprising polymeric core particles coated evenly with a layer of polymer containing magnetically responsive metal oxide. A wide variety of polymeric particles with sizes ranging from 1 to 100 microns can be used as core particles and transformed into magnetically responsive polymer particles. The surface of these magnetically responsive polymer particles can be coated further with another layer of functionalized polymer. These magnetically responsive polymer particles can be used for passive or covalent coupling of biological material such as antigens, antibodies, enzymes or DNA/RNA hybridization and used as solid phase for various types of immunoassays, DNA/RNA hybridization probes assays, affinity purification, cell separation and other medical, diagnostic, and industrial applications.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

5

PROCESS FOR PRODUCING MAGNETICALLY RESPONSIVE
POLYMER PARTICLES AND APPLICATION THEREOF

Field of the Invention

10 This invention relates to a process to make magnetically responsive polymer particles and their use in immunoassays, biomedical and industrial applications.

Background of the Invention

15 Many biological techniques, such as immunoassays, affinity purification etc., require the separation of bound from free fractions. Magnetic particles have been used to facilitate the desired separation.

20 Magnetic particles have been formed from a variety of particulate and magnetic matter, using a variety of processes, having different characteristics. For example, Ikeda et al. U.S. Patent No. 4,582,622, discloses a magnetic particle comprised of gelatin, water-soluble polysaccharide, sodium phosphate and ferromagnetic substances; U.S. Patent Nos. 4,628,037 and 4,554,088
25 discloses magnetic particles comprised of a magnetic metal oxide core surrounded by a coat of polymeric silane; U.S. Patent No. 4,452,773 discloses discrete colloidal sized particles having a core of ferromagnetic iron oxide (Fe_3O_4) which is coated with a water-soluble polysaccharide or a derivative thereof having
30 functional groups; and Mansfield U.S. Patent No. 4,297,337 discloses magnetic glass- or crystal-containing material as a particulate carrier.

- 2 -

Summary of the Invention

The present invention provides a novel process of producing magnetically responsive polymer particles, hereinafter referred to as magnetic particles, from polymeric particles with average size
5 from about 1 to 100 microns in diameter regardless of shape and composition. The magnetic particles of this invention may be prepared by first producing magnetically responsive metal oxide, hereinafter referred to as metal oxide, with average size of about 1 micron or less and then coating a polymeric core particle with a
10 layer of polymer containing metal oxide. The surface of these magnetic particles can be coated further with another layer of polymer or functionalized polymer to provide the desired surface characteristics.

The magnetic particles produced by the present invention are
15 monodispersed in size with rough surface and have a magnetic metal oxide content of from about 5% to 50%, preferably from 10% to 25%. Particles with these characteristics have been found to be useful in immunoassays and a wide variety of biomedical applications. These magnetic particles can be used for passive or covalent coupling of
20 biological material such as antigens, antibodies, enzymes or DNA/RNA and used as solid phase for various types of immunoassays, DNA/RNA hybridization assays, affinity purification, cell separation and other biomedical applications. The magnetic particles can also be used for industrial application such as the treatment of industrial
25 waste.

Objectives and Advantages

It is the objective of this invention to:

Develop a process of producing magnetically responsive polymer particles easily from readily available polymer particles.

30 Develop a process of producing magnetically responsive polymer particles with moderate sedimentation and fast magnetic separation.

Develop a process of producing magnetically responsive polymer particles with various surface charges, and functional groups for passive adsorption or covalent coupling of biological material.

- 3 -

Develop medical, biological, diagnostic and industrial applications using these magnetically responsive polymer particles.

The advantages of this invention include:

5 A wide variety of polymeric core particles with size from about 1 to 100 microns can easily be transformed to magnetically responsive particles.

The metal oxide content can be varied according to the applications.

10 The surface can be derivatized into a wide variety of functional groups for covalent coupling.

A wide variety of monomer can be used for the final coating to provide different surface characteristics of the resulting polymer.

Both crosslinked and noncrosslinked magnetically responsive polymer particles can be produced.

15 Monodispersed magnetically responsive polymer particles can be produced.

Detailed Description of the Invention

20 The magnetic particles of this invention may be prepared by first producing metal oxide with average size of about 1 micron or less. The metal oxide is produced by heating and precipitating a mixture of divalent and trivalent metal salt, preferably a mixture of ferrous and ferric sulfate or chloride with sodium hydroxide solution. The molar ratio of divalent to trivalent metal salt can be varied from 0.5 to 2.0, preferably 0.5 to 1.0, to obtain the
25 desirable size and magnetic characteristics of metal oxide. It is observed that the molar ratio of divalent to trivalent metal salt affects the size of the metal oxide: the smaller the molar ratio of divalent to trivalent metal salt, the smaller the size of metal oxide. The molar ratio of divalent to trivalent metal salt also
30 affects the color of the resulting magnetic particles: the smaller the molar ratio, the lighter the brownish color of the resulting magnetic particles. Preferably, the metal oxide is either superparamagnetic or paramagnetic although ferromagnetic metal oxide can also be used, provided centrifugation instead of magnetic separation is used during the clean up.

- 4 -

Other divalent transition metal salts such as manganese, magnesium, cobalt, nickel, zinc, and copper salts may be substituted for ferrous salt.

After the metal oxide has been precipitated, it is washed
5 several times with centrifugation at 250xg until the supernatant is neutral in pH. The metal oxide is resuspended in deionized water and mechanically stirred at high speed to break down the aggregate of metal oxide crystals. Further centrifugation at 250xg will not
10 pellet all of the metal oxide. The supernatant which contain smaller size metal oxide crystals is collected and the pellet is resuspended in deionized water. This process is repeated for at least three times or until most of metal oxide can no longer be pelleted at 250xg. The metal oxide obtained this way usually has size less than 2.0 micron. Low speed centrifugation at 100xg to
15 remove largers crystals will reduce the size to less than 0.8 micron.

The metal oxide with average size of 1.0 micron or less is mixed with monomer and coated onto the polymeric core particles, preferably polystyrene particles, with size of 1 to 100 microns in the presence of initiator. Addition of a small quantity of
20 emulsifier will help prevent the particles from agglomerating. The magnetic particles are then coated with a protective layer of polymer, preferably polystyrene, to prevent the metal oxide from falling off. If functionalized magnetic particles are desired the magnetic particles can be coated further with another layer of
25 functionalized polymer to provide functional groups such as carboxyl, amino or hydroxyl for covalent coupling of biological material.

The magnetic particles prepared according to this invention can be illustrated in Figure I, where A represents the core particle, B
30 represents the metal oxide/polymer coating, C represents the protective polymer coating and D represents the functionalized polymer coating. Figure II shows the transmission electron micrograph of 0.08 to 0.1 micron slice of a magnetic particle

- 5 -

prepared according to this invention. Figure III shows a scanning electron micrograph of 6.8 micron magnetic particles, prepared according to this invention. Figure III a is at 1000x and Figure III b is at 5000x magnification.

5

10

15

20

25

30

The polymeric core particles useful in this invention may be of any polymer which can be obtained as a dispersion of small particles and which can absorb a monomer thereby causing the metal oxide and monomer mixture to coat onto the surface of the core particles. The core particles may be of any size and shape, preferably of 1 to 100 microns in size and spherical in shape. When monodispersed core particles are used the resulting magnetic particles will also be monodispersed in size. The core particles may be obtained by emulsion polymerization, suspension polymerization or other means of polymerization with or without a crosslinking agent such as divinyl benzene or the like. Among the monomers which can be used to prepare core particles are styrene, methyl methacrylate, vinyltoluene and the like. A mixture of the monomers can also be used. The monomer used for magnetic metal oxide coating or protective coating may or may not be the same type as the core particles. The weight ratio of monomer used for metal oxide coating to core particles may be from 0.1 to 12, preferably from 0.2 to 6, depending upon the thickness of metal oxide/polymer layer desired. When the metal oxide prepared from a mixture of ferrous and ferric salts is used for coating it is preferred to use a monomer to core particle weight ratio of about 0.1 to 0.5. However when the metal oxide prepared from a mixture of manganese (II) and ferric salts is used for coating the weight ratio of monomer to core particles may be from 0.1 to 12. As a result when crosslinked magnetic particles which are inert to common organic solvent are desired, it is preferred to use the metal oxide prepared from a mixture of manganese (II) and ferric salts with monomer containing 2% to 10%, preferably 8% to 10% by weight of crosslinking agent and a monomer to core particle weight ratio of 3 to 12, preferably 4 to 6. When lower monomer to core particle weight ratio (i.e. 0.1 to 0.5) is used during the metal oxide/polymer coating it is preferred to overcoat the resulting magnetic particles with a protective layer of polymer coating to further adhere the metal oxide to the surface of the magnetic particles. However, when higher monomer to core particle

ratio (i.e. 3 to 12) is used no protective polymer coating is necessary. The polymerization temperature may be from 50°C to 90°C, preferably 55°C to 65°C. The polymerization initiator may either be water soluble such as potassium persulfate and the like or water insoluble such as benzoyl peroxide and the like. Other means of polymerization initiation such as radiation, ionization or the like may also be used. It is found unexpectedly that magnetic particles can be produced without using any emulsifier when the metal oxide prepared from a mixture of manganese (II) and ferric salts is used for coating. However, a small amount of emulsifier such as sodium dodecylsulfate, Aerosol 22, Tween 20 or Nonidet P-40 (NP 40) is found to be useful in preventing the particles from extensive aggregation during the metal oxide/polymer coating when the metal oxide prepared from a mixture of ferrous and ferric salts is used for coating. Other emulsifiers with the same capability may also be used. The magnetic metal oxide content can be varied from 5% to 50%, preferably from 10% to 25% by using different amount of metal oxide during the metal oxide/polymer coating. Multiple metal oxide/polymer coatings can also be employed to increase the metal oxide content. Other ingredients commonly used in polymerization may also be added as long as magnetic particles with desirable characteristics can be obtained. The ingredients for metal oxide/polymer coating may be added all at once at the beginning of metal oxide/polymer coating process or added stepwise. When the metal oxide prepared from a mixture of ferrous and ferric salt is used, it is preferred to add the ingredients stepwise. The ingredients may be mixed by mechanic stirring, tumbling or other means of agitation under vacuum or inert gas such as argon. The functional groups can be incorporated onto the surface of the magnetic particles by either using a mixture of monomer and functionalized monomer during the metal oxide/polymer coating or overcoating the magnetic particles with a thin layer of functionalized monomer at the end. The functionalized monomer used may be selected from one or a mixture of the following: 2-hydroxyethyl methacrylate, 2-aminoethyl methacrylate,

trimethylammoniummethyl methacrylate methosulfate, dimethylaminoethyl methacrylate, methacrylic acid, undecylenic acid, methyl propene sulfonic acid, undecylenyl alcohol, oleyl amine, glycidyl methacrylate, acrolein, glutaraldehyde and the like. The magnetic particles can also be overcoated with a layer of different polymer than the one used for metal oxide/polymer coating or protective coating to take up the surface characteristics of that polymer.

Applications of Magnetic Particles

The uses of a wide variety of magnetic particles as solid phase for various applications such as fluorescence immunoassays, radioimmunoassays, enzyme immunoassays, cell separations, enzyme immobilizations and affinity purifications have been reviewed in literature as exemplified by the following articles: Hirschbein et al, Chemical Technology, March 1982, 172-179 (1982); Pourfarzaneh, The Ligand Quarterly, 5(1): 41-47 (1982); Halling and Dunnill, Enzyme Microbe Technology, 2: 2-10 (1980); Mosbach and Anderson, Nature, 270: 259-261 (1977); Guesdon et al, J. Allergy Clinical immunology, 61(1), 23-27 (1978). Some applications have also been disclosed in the U.S. Patent Nos. 4,152,210 and 4,343,901 for enzyme immobilizations; U.S. Patent Nos. 3,970,518, 4,230,685, and 4,267,2343 for cell separations; U.S. Patent Nos. 4,554,088, 4,628,037, and 3,933,997 for immunoassays.

Some magnetic particles may be useful in one application, but not in another application. For example, the magnetic particles disclosed in U.S. Patent No. 4,554,088 and 4,628,037, which comprise a superparamagnetic metal oxide core generally surrounded by a coat of polymeric silane, may be useful in immunoassay and affinity purification, due to the large surface area and slower settling rate, but are not suitable in cell separation application such as bone marrow purging. Due to the small size of the magnetic particles, disclosed in these two patents, it is very difficult to remove all of the magnetic particles from the cell suspension effectively. Moreover, the nonspecific binding of smaller magnetic particles to normal cells would be much higher. In using magnetic particles for bone marrow purging, the magnetic particles are coated

with antibody, such as sheep anti-mouse IgG, and the bone marrow is treated with a mixture of several monoclonal antibodies against the cancer cell surface antigens. The magnetic particles will bind only to the cancer cells and cause them to be separated from normal cells by passing them through a strong magnetic field. The cleansed cells are then put back into the patient.

By using the processes of this invention magnetic particles can be optimized in terms of size, surface area, metal oxide content and surface characteristics for a wide variety of biomedical applications. The magnetic particles produced by this invention can be used as solid phase for enzyme immunoassay, fluorescence immunoassay, radioimmunoassay, DNA/RNA hybridization assay, and other diagnostic applications. Immunoassays can be performed by using various configurations such as sandwich assays and competitive binding assays etc., which are obvious to those skilled in the art. The DNA/RNA hybridization can also be performed by using various configurations such as solid phase hybridization or liquid phase hybridization. In solid phase hybridization configuration a DNA or RNA probe (catcher probe) is immobilized on the magnetic particle first. The immobilized catcher probe is then used to hybridize with complimentary strand of DNA from the sample (sample DNA). Finally another probe (signal probe) which is labeled with fluorescent, radioactive or enzyme tracer and capable of hybridizing with another part of the sample DNA is used for signal generation. In liquid phase hybridization configuration the catcher probe and signal probe are allowed to hybridize with the sample DNA in the liquid phase first and then immobilized to the magnetic particles.

Alternatively, the signal probe can also be labelled with one or several biotin groups and the signal is detected by binding the biotin groups with avidin labelled fluorescent, radioactive or enzymatic tracer to enhance the sensitivity of the assay.

The immunoassays and DNA/RNA hybridization assays can be used to measure a wide variety of compounds such as drugs, hormones, antibodies, peptides, DNA, RNA, nucleotides, viral antigens, and carbohydrates in biological samples.

The magnetic particles produced by this invention can also be used for affinity purification, cell separation, enzyme immobilization and other biomedical applications. In cell separation the magnetic particles are used to either remove unwanted cells (negative selection) or enrich the wanted cells (positive selection) through immunological reactions or nonimmunological reactions. This principle can be used to remove cancer cells from bone marrow (bone marrow purging), purify cell populations through either positive or negative selection for tissue culture and perform various cellular immunoassays etc. In affinity purification the magnetic particles are used in place of conventional solid phase such as polyacrylamide gels, sepharose gels or other cellulose beads to purify a wide variety of biological materials such as antibodies, antigens, enzymes, inhibitors, cofactors, single stranded DNA, binding proteins, haptens and carbohydrates etc. In another application similar to the affinity purification, the magnetic particles can be used to cross adsorb and remove unwanted protein components from the antisera or clinical samples. In enzyme immobilization the enzyme is immobilize onto the magnetic particles through various means of coupling so as to preserve the enzyme activity and to permit the reuse of immobilized enzyme. The magnetic particles with immobilized enzyme can be used to replace other solid phases such as glass beads, controlled pore glass, silica gels and cellulose beads etc., which are commonly used in immobilized enzyme systems to produce a wide variety of materials such as carbohydrates, amino acids, and proteins, etc.

The magnetic particles produced by this invention can be used for industrial applications like the treatment of industrial waste, to remove harmful chemicals, i.e. organic or inorganic solvents from industrial material.

These applications are all facilitated by the ease of separation, fast reaction rate and large surface area common to most of magnetic particles. The following examples are provided to further illustrate the versatility and advantages of this invention,

the details thereof are not to be construed as limitations, for it will be apparent that various equivalents, changes and modifications may be resorted to without departing from the spirit and scope thereof and it is understood that such equivalent embodiments are intended to be included therein.

General Procedures for the Preparation of Metal Oxide

Example 1

In a three-necked round bottom flask equipped with mechanical stirrer, condenser, thermometer, dropping funnel and heating mantle was placed a mixture containing 0.361 mol of ferrous sulfate and 0.369 mol of ferric sulfate ($\text{Fe}^{++}/\text{Fe}^{+++}$ ratio = 1) in 400 ml of deionized water. The mixture was heated to 85 to 90 °C with stirring and added dropwise 850 ml of 6 N sodium hydroxide over a period of 90 minutes. The mixture was stirred at 85 to 90 °C for one more hour and cooled to room temperature. The metal oxide precipitates were centrifuged at 250xg for 10 minutes. The clear supernatant was decanted and the pellet was resuspended in 900 ml of deionized water using mechanical stirrer. This cleaning process was repeated six times or until the supernatant was almost neutral in pH. The supernatant was decanted and resuspended in 200 ml of deionized water. Further centrifugation at 250xg will not pellet all of the metal oxide precipitates. The supernatant which contained smaller size metal oxide crystals was collected and the pellet was resuspended in 200 ml of deionized water. This process was repeated for at least three times or until most of metal oxide can no longer be pelleted at 250xg. The metal oxide obtained this way usually has size less than 2.0 micron. The combined metal oxide suspension was centrifuged at 100xg for 10 minutes. The supernatant was collected to give 800 ml of 8.6 % w/v magnetic metal oxide suspension having the size less than 0.8 microns.

Example 2

Same procedures as described in Example 1 were followed except 0.235 mol of ferrous sulfate, 0.297 mol of ferric sulfate ($\text{Fe}^{++}/\text{Fe}^{+++}$ ratio = 0.79) in 400 ml of deionized water and 480

ml of 6 N sodium hydroxide were used to give 2000 ml of 2.86 % w/v suspension of magnetic metal oxide.

Example 3

5 Same procedures as described in Example 1 were followed except 0.178 mol of ferrous sulfate, 0.298 mol of ferric sulfate ($\text{Fe}^{++}/\text{Fe}^{+++}$ ratio = 0.59) in 400 ml of deionized water and 520 ml of 6 N sodium hydroxide were used to give 1500 ml of 2.98 % w/v suspension of magnetic metal oxide.

Example 4

10 Same procedures as described in Example 1 were followed except 0.15 mol of ferrous sulfate, 0.276 mol of ferric sulfate ($\text{Fe}^{++}/\text{Fe}^{+++}$ ratio = 0.54) in 400 ml of deionized water and 520 ml of 6 N sodium hydroxide were used to give 700 ml of 6.88 % w/v suspension of magnetic metal oxide.

Example 5

15 Same procedures as described in Example 1 were followed except 0.116 mol of manganese sulfate, 0.146 mol of ferric sulfate ($\text{Mn}^{++}/\text{Fe}^{+++}$ ratio = 0.79) in 225 ml of deionized water and 240 ml of 6 N sodium hydroxide were used to give 1700 ml of 1.8 % w/v suspension of magnetic metal oxide.

Preparation of Magnetic Particles

Example 6

25 A mixture containing 600 ml of deionized water, 6 ml of styrene and 80 ml of 8.6 % w/v magnetic metal oxide prepared as described in Example 1, was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for one hour. To the mixture were added 12 g of potassium persulfate and 850 ml of 5 % w/v, 4.0 micron polystyrene particles. The bottle was resealed, evacuated and rotated for one hour and added 50 ml of 2 % sodium
30 dodecylsulfate. After five more hours 6 ml of styrene and 10 g of potassium persulfate were added to the mixture. The mixture was rotated for another fifteen hours, filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting

magnetic particles were resuspended to 1.6 l with deionized water to give a 2.5 % w/v suspension with about 11 % magnetic metal oxide content and 4.3 micron average size.

Example 7

5 The magnetic particles, 1.6 l of 2.5 % w/v, prepared as described in Example 6, were carboxylated by adding 1 g of sodium dodecylsulfate, 10 g of potassium persulfate and a solution
10 containing 0.98 ml of undecylenic acid and 0.02 ml of divinyl benzene in 4 ml of methanol. The mixture was placed in a sealed bottle, evacuated and rotated at about 60 rpm in a 55 °C oven for 5 hours. The resulting carboxyl magnetic particles were separated magnetically and washed several times with deionized water until the supernatant was clear. The carboxyl magnetic particles were
15 resuspended to 680 ml with deionized water to give a 5.8 % w/v suspension with about 11 % magnetic metal oxide content and 4.3 micron average size.

Example 8

20 A mixture containing 600 ml of deionized water, 6 ml of styrene and 80 ml of 8.6 % w/v magnetic metal oxide prepared as described in Example 1, was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for one hour. To the mixture were added 12 g of potassium persulfate and 850 ml of 4.78 % w/v, 6.1 micron polystyrene particles. The bottle was resealed, evacuated, rotated for five hours and added 6 ml of styrene and 10 g
25 of potassium persulfate. The mixture was rotated for another fifteen hours, filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 1.5 l with deionized water and carboxylated by
30 adding 1 g of sodium dodecylsulfate, 10 g of potassium persulfate and a solution containing 0.98 ml of undecylenic acid and 0.02 ml of divinyl benzene in 4 ml of methanol. The mixture was placed in a sealed bottle, evacuated and rotated at about 60 rpm in a 55 °C oven for 5 hours. The resulting carboxyl magnetic particles were separated magnetically and washed several times with deionized water

until the supernatant was clear. The carboxyl magnetic particles were resuspended to 800 ml with deionized water to give a 4.3 % suspension with about 11.6 % magnetic metal oxide content and 6.8 micron average size.

5 Example 9

10 A mixture containing 600 ml of deionized water, 6 ml of styrene and 60 ml of 8.6 % w/v magnetic metal oxide prepared as described in Example 1, was placed in a three-necked round bottom flask and stirred at 67 °C for one hour under argon. To the mixture were
15 added 12 g of potassium persulfate and 470 ml of 5 % w/v, 2.7 micron polystyrene particles. The mixture was stirred at 67 °C for one hour and added 30 ml of 2 % sodium dodecylsulfate. After stirring at 67 °C under argon for five more hours 6 ml of styrene and 6 g of
20 potassium persulfate were added to the mixture. The mixture was stirred at 67 °C under argon for another fifteen hours, filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 900 ml with deionized water and carboxylated by adding 0.6 g of sodium
25 dodecylsulfate, 10 g of potassium persulfate and a solution containing 0.598 ml of undecylenic acid and 0.012 ml of divinyl benzene in 2.4 ml of methanol. The mixture was placed in a sealed bottle, evacuated and rotated at about 60 rpm in a 55 °C oven for 5 hours. The resulting carboxyl magnetic particles were separated
30 magnetically and washed several times with deionized water until the supernatant was clear. The carboxyl magnetic particles were resuspended to 500 ml to give a 6.5 % w/v suspension with about 14 % magnetic metal oxide content and 4.0 micron average size.

30 Example 10

30 A mixture containing 600 ml of deionized water, 6 ml of styrene and 60 ml of 8.6 % w/v magnetic metal oxide prepared as described in Example 1, was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for one hour. To the mixture were added 12 g of potassium persulfate and 470 ml of 5 % w/v, 2.7 micron polystyrene particles. The bottle was resealed,

evacuated and rotated for one hour and added 30 ml of 2 % sodium dodecylsulfate. After five more hours 6 ml of styrene and 10 g of potassium persulfate were added to the mixture. The mixture was rotated for another fifteen hours, filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 500 ml with deionized water to give a 6.8 % w/v suspension with about 14 % magnetic metal oxide content and 4.0 micron average size.

10 Example 11

A mixture containing 180 ml of deionized water, 2 ml of styrene and 20 ml of 8.6 % w/v magnetic metal oxide, prepared as described in Example 1, was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for one hour. To the mixture were added 4 g of potassium persulfate and 160 ml of 6.8 % w/v magnetic particles (3.0 micron, 14 % metal oxide content), prepared as described in Example 10. The bottle was resealed, evacuated and rotated for one hour and added 10 ml of 2 % sodium dodecylsulfate. After 5 more hours 2 ml of styrene and 2 g of potassium persulfate were added to the mixture. The mixture was rotated for another fifteen hours, filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 160 ml with deionized water to give a 7.78 % w/v suspension with about 19 % metal oxide content and 4.2 micron average size.

25 Example 12

A mixture containing 90 ml of deionized water, 1 ml of styrene and 10 ml of 8.6 % w/v magnetic metal oxide, prepared as described in Example 1, was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for one hour. To the mixture were added 1 g of potassium persulfate and 80 ml of 7.78 % w/v magnetic particles (3.2 micron, 19 % metal oxide content), prepared as described in Example 11. The bottle was resealed, evacuated and rotated for four hour and added 5 ml of 2 %

sodium dodecylsulfate. After 5 more hours 1 ml of styrene and 1 g of potassium persulfate were added to the mixture. The mixture was rotated for another fifteen hours, filtered through two layers of cheese cloth, separated magnetically and washed several times with
5 deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 160 ml with deionized water to give a 4.5 % w/v suspension with about 23 % metal oxide content and 4.5 micron average size.

Example 13

10 A mixture containing 400 ml of deionized water, 1.92 ml of styrene, 0.08 ml of divinyl benzene, 4 g of potassium persulfate, 20 g of 200 - 400 mesh 4 % divinyl benzene cross linked polystyrene beads and 10 ml of 8.6 % w/v magnetic metal oxide, prepared as described in Example 1, was placed in a sealed bottle. The bottle
15 was evacuated and rotated at about 60 rpm in a 55 °C oven for 15 hours. The mixture was allowed to settle and the supernatant was decanted. The resulting magnetic beads were resuspended in 200 ml of deionized water and allowed to settle again. This process was repeated several times until the supernatant was clear. The
20 resulting magnetic beads were resuspended in 200 ml of deionized water and added 0.1 g of sodium dodecyl sulfate, 2.0 g of potassium persulfate, 0.48 ml of styrene, and 0.02 ml of divinyl benzene. The bottle was resealed, evacuated and rotated at about 60 rpm in a 55 °C oven for one hour and added a solution containing 0.098 ml of
25 undecylenic acid and 0.002 ml of divinyl benzene in 0.4 ml of methanol. The mixture was rotated for four more hours and cleaned up by gravitational sedimentation as described previously. The water was removed by filtration and the carboxyl magnetic beads were dried to give 20 g of 200 - 400 mesh carboxyl magnetic beads.

30 Example 14

A mixture containing 100 ml of deionized water, 0.5 ml of styrene, 2 g of potassium persulfate, 75 ml of 5 % w/v 4.0 micron polystyrene particles and 10 ml of 6.88 % w/v magnetic metal oxide, prepared as described in Example 4, was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven

for fifteen hours. The mixture was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 150 ml with deionized to give a 2.5 % w/v suspension with about 14 % metal oxide content and 4.3 micron average size.

Example 15

Same procedures as described in Example 14 were followed except 20 ml of 6.88 % w/v magnetic metal oxide, prepared as described in Example 4, was used to give 160 ml of 2.5 % w/v suspension with about 18 % metal oxide content and 4.3 micron average size.

Example 16

A mixture containing 2000 ml of deionized water, 13 ml of styrene and 550 ml of 2.98 % w/v magnetic metal oxide prepared as described in Example 3, was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for one hour. To the mixture were added 20 g of potassium persulfate and 950 ml of 10 % w/v, 3.0 micron polystyrene particles. The bottle was resealed, evacuated and rotated for one hour and added 60 ml of 2 % sodium dodecylsulfate. After five more hours 8 ml of styrene and 10 g of potassium persulfate were added to the mixture. The mixture was rotated for another fifteen hours, filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 3000 ml with deionized water to give a 3.38% w/v suspension with about 12 % magnetic metal oxide content and 3.2 micron average size.

Example 17

A mixture containing 150 ml of magnetic particles (3.2 micron, 3.38 % w/v with 12 % metal oxide content) prepared as described in Example 16, 2 ml of 1 % NP 40, 0.5 ml of methyl methacrylate or styrene, 1 g of potassium persulfate and 2 ml of functionalized monomer, trimethylammoniummethyl methacrylate methosulfate (40 % aqueous solution), was placed in a sealed bottle. The bottle was rotated at about 60 rpm in a 55 °C oven for four hours. The mixture

was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 200 ml with deionized water to give a 2.5 % w/v suspension of magnetic particles with trimethylammonium functional groups on the surface.

Example 18

Same procedures as described in Example 17 were followed except 1 ml of functionalized monomer, 2-aminoethyl methacrylate, was used to give 200 ml of 2.5 % w/v suspension of magnetic particles with amino groups on the surface.

Example 19

Same procedures as described in Example 17 were followed except 1 ml of functionalized monomer, 2-hydroxyethyl methacrylate, was used to give 200 ml of 2.5 % w/v suspension of magnetic particles with hydroxyl groups on the surface.

Example 20

Same procedures as described in Example 17 were followed except 1 ml of monomer, 1-vinyl-2-pyrrolidinone, was used to give 200 ml of 2.5 % w/v suspension of magnetic particles with polyvinylpyrrolidinone on the surface.

Example 21

Same procedures as described in Example 17 were followed except 1 g of functionalized monomer, methyl propene sulfonic acid, was used to give 200 ml of 2.5 % w/v suspension of magnetic particles with sulfonic acids groups on the surface.

Example 22

Same procedures as described in Example 17 were followed except 1 ml of functionalized monomer, dimethylaminoethyl methacrylate, was used to give 200 ml of 2.5 % w/v suspension of magnetic particles with dimethylamino groups on the surface.

Example 23

A mixture containing 20 ml of 7.0 % w/v, 2.11 micron polystyrene particles, 100 ml of 1.8 % w/v metal oxide prepared as described in Example 5, 50 ml of deionized water and a solution containing 0.15 g

of benzoyl peroxide in 7.5 ml of styrene was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for fifteen hours. The mixture was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting magnetic particles were resuspended to 200 ml with deionized water to give 5.0 % w/v suspension with about 16.8 % metal oxide content and 3.6 micron average size.

Example 24

10 A mixture containing 20 ml of 7.0 % w/v, 2.11 micron polystyrene particles, 100 ml of 1.8 % w/v metal oxide prepared as described in Example 5, 50 ml of deionized water and a solution containing 0.15 g of benzoyl peroxide and 0.75 ml of divinyl benzene in 6.75 ml of styrene was placed in a sealed bottle. The bottle was evacuated and
15 rotated at about 60 rpm in a 55 °C oven for fifteen hours. The mixture was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting crosslinked magnetic particles were resuspended to 200 ml with deionized water to give 5.0 % w/v
20 suspension with about 16.8 % metal oxide content and 3.6 micron average size. The crosslinked magnetic particles prepared this way were found to be uniform in size and inert to common organic solvents such as acetone, acetonitrile and dimethyl formamide.

Example 25

25 A mixture containing 20 ml of 7.0 % w/v, 2.11 micron polystyrene particles, 150 ml of 1.8 % w/v metal oxide prepared as described in Example 5 and a solution containing 0.15 g of benzoyl peroxide, 0.75 ml of divinyl benzene in 6.75 ml of styrene was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a
30 55 °C oven for fifteen hours. The mixture was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting crosslinked magnetic particles were resuspended to 200 ml with deionized water to give 5.4 % w/v suspension with about 23 % metal oxide content and 4.0 micron average size. The crosslinked

magnetic particles prepared this way were found to be uniform in size and inert to common organic solvents such as acetone, acetonitrile and dimethyl formamide.

Example 26

5 A mixture containing 15 ml of 9.16 % w/v, 3.2 micron polystyrene particles, 100 ml of 1.8 % w/v metal oxide prepared as described in Example 5, 55 ml of deionized water and a solution containing 0.15 g of benzoyl peroxide and 0.75 ml of divinyl benzene in 6.75 ml of
10 styrene was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for fifteen hours. The mixture was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting crosslinked magnetic particles were resuspended to 200 ml with deionized water to give 4.7 % w/v
15 suspension with about 16.8 % metal oxide content and 5.5 micron average size. The crosslinked magnetic particles prepared this way were found to be uniform in size and inert to common organic solvents such as acetone, acetonitrile and dimethyl formamide.

Example 27

20 A mixture containing 30 ml of 4.5 % w/v, 4.1 micron polystyrene particles, 100 ml of 1.8 % w/v metal oxide prepared as described in Example 5, 40 ml of deionized water and a solution containing 0.15 g of benzoyl peroxide and 0.75 ml of divinyl benzene in 6.75 ml of
25 styrene was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for fifteen hours. The mixture was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting crosslinked magnetic particles were resuspended to 200 ml with deionized water to give 4.5 % w/v
30 suspension with about 16.9 % metal oxide content and 6.7 micron average size. The crosslinked magnetic particles prepared this way were found to be uniform in size and inert to common organic solvents such as acetone, acetonitrile and dimethyl formamide.

Example 28

A mixture containing 20 ml of 7.0 % w/v, 2.11 micron polystyrene particles, 100 ml of 1.8 % w/v metal oxide prepared as described in Example 5, 50 ml of deionized water and a solution containing 0.15 g of benzoyl peroxide, 0.75 ml of undecylenyl alcohol and 0.75 ml of divinyl benzene in 6 ml of styrene was placed in a sealed bottle. The bottle was evacuated and rotated at about 60 rpm in a 55 °C oven for fifteen hours. The mixture was filtered through two layers of cheese cloth, separated magnetically and washed several times with deionized water until the supernatant was clear. The resulting crosslinked hydroxyl magnetic particles were filtered and dried to give 9 g of powder with about 16.8 % metal oxide content and 3.9 micron average size. The crosslinked hydroxyl magnetic particles prepared this way were found to be uniform in size and inert to common organic solvents such as acetone, acetonitrile and dimethyl formamide.

Coupling Biological Materials to Magnetic ParticleExample 29

In a 80 ml bottle was placed 30 ml of 4.3 micron, 5.0 % w/v carboxyl magnetic particles prepared as described in Example 7. The particles were separated magnetically and resuspended in 50 ml of phosphate buffer (0.1 M, pH 5.5). To the particle suspension were added 20 mg of bovine serum albumin and 100 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC). The mixture was rotated end to end at room temperature for two hours and separated magnetically. The particles were washed once with 80 ml of phosphate buffer and resuspended to 75 ml with phosphate buffered saline (0.1 M, pH 7.0) to give a 2.0 % w/v suspension.

To couple bovine serum albumin to magnetic particles by passive adsorption the same procedures were followed except no EDC was used.

Example 30

In a 4 ml vial was placed 1 ml of 4.3 micron, 5.0 % w/v carboxyl magnetic particles prepared as described in Example 7. The particles were separated magnetically and washed once with 2 ml of

phosphate buffer (0.1 M, pH 5.5) and resuspended to 2 ml with the same buffer. To the particles suspension were added 140 µl of 1.4 mg/ml Goat (Gt) anti Mouse (Ms) IgG and 10 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. The vial was rotated end to end at room temperature for two hours. The particles were separated magnetically, washed once with 2 ml of phosphate buffer and resuspended to 2 ml with phosphate buffered saline (0.1 M, pH 7.0) to give a 2.5 % w/v Gt anti Ms IgG coated magnetic particles. Other kind of antibody either monoclonal or polyclonal could also be coupled to carboxyl magnetic particles by using the same procedures.

To couple Gt anti Ms IgG or other kind of antibody to the magnetic particles by passive adsorption the same procedures were followed except no EDC was used.

Example 31

In a 4 ml vial was placed a 2.5 ml of bovine serum albumin coated magnetic particles (4.3 micron, 2 % w/v) prepared as described in Example 29. The particles were separated magnetically and resuspended to 2 ml with phosphate buffer (0.1 M, pH 5.5). To the mixture were added 10 µl of Ms anti B red cells surface antigen (20 mg/ml) and 1 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide. The mixture was rotated end to end at room temperature for two hours. The particles were separated magnetically, washed once with phosphate buffer and resuspended in 2 ml of phosphate buffered saline (0.1 M, pH 7.0) to give a 2.5 % w/v suspension.

Example 32

Same procedures as described in Example 31 were followed except using 40 µl of Ms anti A red cells surface antigen (5 mg/ml) to give 2 ml of 2.5 % w/v suspension.

Blood Typing Using Magnetic Particles

Example 33

In a 5mm x 65mm test tube labeled A was placed 25 µl of 2.5 % w/v Ms anti A coated magnetic particles prepared as described in Example 32. To the other test tube labeled B was placed 25 µl of

2.5 % w/v Ms anti B coated magnetic particles prepared as described in Example 31. To both test tubes was added 50 ul of 1 % packed red blood cells prepared by 1 to 100 dilution of packed red blood cells in isotonic buffered saline. The test tubes were shaken by finger tapping for several times and placed on the top of a magnet. The results were summarized as follows:

		BLOOD TYPE			
		A	B	O	AB
10	TUBE A	+	-	-	+
	TUBE B	-	+	-	+

Where + represent a positive reaction, meaning the red cells were agglutinated by the corresponding antibody coated magnetic particles as a result the supernatant in the test tube was clear after magnetic separation. On the other hand the supernatant of a negative reaction would remain cloudy after magnetic separation due to the absence of agglutination between the red cells and the antibody coated magnetic particles.

Immunoassays Using Magnetic Particles

Example 34

20 In a 2 ml microcentrifuge tube was placed 1 ml of 6 % w/v, 3 micron carboxyl magnetic particles. The particles were centrifuged for 3 minutes at 10000 rpm. The supernatant was aspirated and the particles were resuspended by vortexing with 1 ml of 5 to 100 ug/ml recombinant HBcAg in acetate buffer. The tube was rotated at room temperature for two hours and centrifuged as described before. The supernatant was aspirated and the particles were resuspended in 1 ml of overcoat solution containing acetate buffer and 2 to 10 % of normal animal serum. The tube was rotated at room temperature for 2 to 16 hours and centrifuged as described before. The supernatant was aspirated and the particles were washed three times with 1 ml of isotonic buffered saline (IBS) by centrifugation and resuspension. Finally, the particles were resuspended with 1 ml of IBS and stored at 2 to 8°C.

Example 35

To the first two columns of a 96-well microtiter plate was placed 20 ul of 0.25% w/v hepatitis B core antigen (HBcAg) coated magnetic particles prepared as described in Example 34. Sample preparation consisted of various dilutions of a HBcAb positive serum into a negative plasma, followed by a 1:100 dilution of each sample into specimen dilution buffer (SDB). The SDB contained phosphate buffer, protein stabilizers, detergent and antimicrobial agents. To the wells containing the particles were added 50 ul of each final sample dilution. After 30 minutes incubation at 37°C, the particles were separated for two minutes on a magnetic separator and washed three times with 200 ul wash buffer containing salts and detergent. To each well containing the particles was added 50 ul of goat antihuman IgG-B-D-galactosidase conjugate (0.5 ug/ml) in diluent containing salts, protein stabilizers, glycerol, detergent and antimicrobial agents. After 15 minutes incubation at 37°C the particles were separated and washed three times as described above and resuspended in 30 ul of IBS. The particles were transferred to the first two columns of a black microtiter plate (Dynatech). To each well containing the particles was added 100 ul of a solution containing 4-methylumbelliferyl-B-galactopyranoside (MUG, Sigma). The plate was incubated at 37°C and the fluorescence intensity was measured by using a Fluorescence Concentration Analyzer (FCA, Pandex) equipped with 365 nm excitation and 450 nm emission filters at five minutes interval and 10 X gain setting. The increase in fluorescence intensity in a five minutes interval was recorded in arbitrary fluorescence unit (AFU) and presented in Table I.

TABLE I

	Dilution of Positive Specimen	AFU (5 Minutes) Average of Two Wells
5	1:100	22687
	1:1000	5933
	1:5000	1516
	1:8000	835
	1:10000	639
10	1:15000	495
	1:20000	427
	1:25000	307

Example 36

15 The coupling of mouse antiHBsAg to carboxyl magnetic particles was similar to Example 30.

To the wells of a black 96-well microtiter plate (Dynatech) were added 20 ul of 0.25% w/v, 3.2 micron, mouse antiHBsAg coated carboxyl magnetic particles in duplicate. To the wells containing the magnetic particles was added 100 ul of neat plasma containing various amounts of HBsAg or a HBsAg-negative plasma. After 30 minutes incubation at 37°C, the particles were separated for two minutes on a magnetic separator and washed once with 100 ul of wash buffer containing salts and detergent. To each well containing the particles was added 20 ul of mouse antiHBsAg--B-galactosidase conjugate in diluent containing salts, protein stabilizers, glycerol, detergent and antimicrobial agents. After 15 minutes incubation at 37°C, the particles were separated and washed five times as described above. To each well containing the particles was added 50 ul of a solution containing 4-methylumbelliferyl-B-D-galactopyranoside (MUG, Sigma). The plate was incubated at 37°C and the fluorescence intensity was measured by using a Fluorescence Concentration Analyzer (FCA, Pandex) equipped with 365 nm excitation

and 450 nm emission filters at five minutes interval and 10 X gain setting. The increase in fluorescence intensity in a five minutes interval was recorded in arbitrary fluorescence unit (AFU) and presented in Table II.

5

TABLE II

	HBsAg Conc. (nano gm)	AFU (5 Minutes) Average of Two Wells
10	1.0	1149
	0.5	455
	0.25	218
	0.125	118
15	neg.	14

Example 37

The HIV-1 antigens from HTLV-IIIB/H-9 cells (Gallo Strain) were coupled to 3.6 micron carboxyl magnetic particles by using similar procedures as described in Example 34.

20

To the wells of a 96-well microtiter plate were added 20 ul of 0.25% w/v of HIV coated magnetic particles in duplicate. To the wells containing the particles were added 50 ul of positive, borderline and negative specimens diluted 1:100 in specimen dilution buffer (SDB) containing phosphate buffer, protein stabilizers, detergent and antimicrobial agents. After 30 minutes incubation at 37°C, the particles were separated for two minutes on a magnetic separator and washed three times with 100 ul of washed buffer containing salts and detergent. To each well containing particles was added 50 ul of goat antihuman-B-galactosidase (approximately 0.5 ug/ml) conjugate in diluent containing salts, protein stabilizers, glycerol, detergent and antimicrobial agents. After 15 minutes incubation at 37°C, the particles were washed four times as described above. The particles were transferred to the black microtiter plate (Dynatech). To each well containing particles was

30

added 100 μ l of a solution containing 4-methylumbelliferyl-B-D-galactopyranoside (MUG, Sigma). The plate was incubated at 37°C and the fluorescence intensity was measured by using a Fluorescence Concentration Analyzer (FCA, Pandex) equipped with 365 nm excitation and 450 nm emission filters at five minutes intervals and 25 X gain setting. The increase in fluorescence intensity in a five minutes interval was recorded in arbitrary fluorescence unit (AFU) and presented in Table III.

10

TABLE III

15

Anti-HIV Specimens	AFU (5 minutes) Average of Two Wells
Positive Control	9462
Borderline Specimen	527
Negative Control	86

Cell Separation Using Magnetic Particles

Example 38

20

25

The 4.3 micron carboxyl magnetic particles prepared as described in Example 7 were washed and sonicated in phosphate buffered saline (PBS, pH 7.7), sterilized in 70% ethanol for 10 minutes, washed three times in PBS and incubated for 48 hours at 4°C with affinity-purified sheep anti-mouse immunoglobulin antibody (SAM) at 0.5 mg/ml and a ratio of 3.3 mg antibody/100mg particles. Before use, the antibody coated magnetic particles were washed in PBS and resuspend at the desired concentration in PBS.

30

Human tissue culture CALLA-positive NALM-16 leukemia cells were washed and suspended in PBS. One fraction was not treated with antibody (-MoAb). The other fraction was treated with two anti-CD10 and one anti-CD9 monoclonal antibodies (+MoAb) for 30 minutes at 4°C, washed in PBS and adjusted to 3.5×10^6 cells/ml on PBS. To two tubes, one containing the antibody treated cells (+MoAb), the other containing untreated cells (-MoAb) were added SAM coated magnetic particles at a particle to starting cell ratio of 45. The

tubes were rotated at 4°C for 30 minutes. The particles were separated with a magnetic separator. The supernatant was collected and centrifuged to collect the remaining cells. The pellet was resuspended in 100 ul of trypan blue and total cell count was made.

5 The results were presented in Table IV.

TABLE IV

10	Particle/cell Ratio	Cells +/- MoAb	Cells Received	% Depletion
	0	+	7.62×10^5	0 (Control)
	45	+	2.89×10^4	96.2
	45	-	7.33×10^5	4.6

15

20

25

30

WHAT IS CLAIMED IS:

1. A magnetic particle comprising:
an inner core polymer particle and;

5 a magnetically responsive metal oxide/polymer coating
evenly covering said inner core particle.
2. The particle of Claim 1 wherein said core particle is comprised
of polystyrene or cross-linked polystyrene.
- 10 3. The particle of Claim 1 wherein said core particle ranges from
about 1 to 100 microns.
4. The particle of Claim 1 wherein said magnetically responsive
15 metal oxide is about 1 micron or less.
5. The particle of Claim 1 wherein said magnetically responsive
metal oxide/polymer coating is formed from either
superparamagnetic, paramagnetic, or ferromagnetic metal oxide.
- 20 6. The particle of Claim 1 wherein said responsive metal
oxide/polymer coating is formed from polystyrene, cross-linked
polystyrene, functionalized polystyrene or other olefinic
monomers.
- 25 7. The particle of Claim 1 wherein the metal oxide is formed from
transition metal salts.
8. The particle of Claim 1 having additional metal oxide/polymer
30 coating evenly covering said first metal oxide/polymer coating.
9. A magnetic particle comprising:

An inner core polymer particle;

A magnetically responsive metal oxide/polymer coating evenly covering said inner core particle; and

an outer polymer coating covering said magnetically responsive metal oxide/polymer coating.

10. The particle of Claim 8 wherein said core particle is comprised of polystyrene or cross-linked polystyrene.

11. The particle of Claim 8 wherein said core particle ranges from about 1 to 100 microns.

12. The particle of Claim 8 wherein said magnetically responsive metal oxide particle is about 1 micron or less.

13. The particle of Claim 8 wherein said magnetically responsive metal oxide/polymer coating is formed from either superparamagnetic, paramagnetic, or ferromagnetic metal oxide.

14. The particle of Claim 8 wherein said magnetically responsive metal oxide/polymer coating is formed from polystyrene, cross-linked polystyrene, functionalized polystyrene or other olefinic monomers.

15. The particle of Claim 8 wherein the metal oxide is formed from transition metal salts.

16. The particle of Claim 8 having additional metal oxide/polymer coating evenly covering said first metal oxide/polymer coating.

17. The magnetic particle of Claim 8 wherein said outer polymer coating is formed from the group consisting of polystyrene, cross-linked polystyrene, functionalized polystyrene or other olefinic monomers.

18. A magnetic particle comprising:

An inner core polymer particle;

5 A magnetically responsive metal oxide/polymer coating evenly covering said inner core particle;

an outer polymer coating covering said magnetically responsive metal oxide/polymer coating and;

10 a layer of functionalized polymer covering said outer polymer coating.

15 19. The particle of Claim 18 wherein said core particle is comprised of polystyrene, cross-linked polystyrene, or other polymers.

20. The particle of Claim 18 wherein said core particle ranges from about 1 to 100 microns.

20 21. The particle of Claim 18 wherein said magnetically responsive metal oxide particle is about 1 micron or less.

25 22. The particle of Claim 18 wherein said magnetically responsive metal oxide/polymer coating is formed from either superparamagnetic, paramagnetic, or ferromagnetic metal oxide.

30 23. The magnetic polymer of Claim 18 wherein said functionalized polymer is selected from the group of compounds which provide carboxyl, amino or hydroxyl functional groups for coupling to biological material.

24. The magnetic polymer of Claim 18 wherein said functionalized polymer is coupled to biological material.

25. The particle of Claim 18 wherein said magnetically responsive metal oxide/polymer coating is formed from polystyrene, cross-linked polystyrene or functionalized polystyrene.
- 5 26. The particle of Claim 18 having additional metal oxide/polymer coating evenly covering said first metal oxide/polymer coating.
27. The particle of Claim 18 wherein the metal oxide is formed from transition metal salts.
- 10 28. A magnetic particle comprising:
- An inner core polymer particle;
- 15 A magnetically responsive metal oxide/polymer coating evenly covering said inner core particle and;
- a layer of functionalized polymer covering said outer polymer coating.
- 20 29. The particle of Claim 28 wherein said core particle is comprised of polystyrene, cross-linked polystyrene or other polymers.
30. The particle of Claim 28 wherein said core particle ranges from about 1 to 100 microns.
- 25 31. The particle of Claim 28 wherein said magnetically responsive metal oxide particle is about 1 micron or less.
- 30 32. The particle of Claim 28 wherein said magnetically responsive metal oxide/polymer coating is formed from either superparamagnetic, paramagnetic, or ferromagnetic metal oxide.
33. The magnetic polymer of Claim 28 wherein said functionalized polymer is coupled to biological material.

34. The particle of Claim 28 wherein said magnetically responsive metal oxide/polymer coating is formed from polystyrene, cross-linked polystyrene or functionalized polymer.

5 35. The particle of Claim 28 wherein the metal oxide is formed from transition metal salts.

36. The particle of Claim 28 having additional metal oxide/polymer coating evenly covering said first metal oxide/polymer coating.

10

37. The process to make a magnetically responsive polymer particle having a polymeric core particle evenly covered by a metal oxide/polymer coating comprising:

15 collecting metal oxide particles of about 1 micron or less;

mixing said metal oxide particles with a monomer to form metal oxide/polymer coating and;

20 coating a polymeric core particle in the presence of an initiator with said metal oxide/polymer particle.

38. The process of Claim 37 wherein said metal oxide/polymer particle is produced by:

25 (a) heating and precipitating said metal oxide/polymer particles with a mixture of divalent and trivalent transition metal salts with sodium hydroxide;

30 (b) washing said precipitate metal oxide/polymer particles until neutral in pH;

(c) resuspending said metal oxide/polymer particles in deionized water;

(d) stirring said metal oxide/polymer particles to break the aggregate of the metal oxide/polymer particle and;

(e) low speed centrifugation to narrow the size distribution of said metal oxide/polymer particles.

39. The process of Claim 37 wherein the metal oxide/polymer particle is mixed with a monomer or monomers to form a metal oxide/polymer coating said monomer are selected from the group consisting of styrene, divinylbenzene, methyl methacrylate, glycidyl methacrylate, and other olefinic monomers.

40. The process of Claim 37 wherein said polymeric core particle is between 1 to 100 microns.

41. The process to make magnetically responsive metal oxide biological material bearing polymer particles having a polymeric core particle evenly covered by a metal oxide/polymer coating comprising:

collecting metal oxide particles of about 1 micron or less;

mixing said metal oxide particles with a monomer to form metal oxide/polymer coating and;

coating a polymeric core particle in the presence of an initiator with said metal oxide/polymer particle.

42. The process of Claim 41 wherein said metal oxide/polymer particle is produced by:

(a) heating and precipitating said metal oxide/polymer particles with a mixture of divalent and trivalent transition metal salts with sodium hydroxide;

- (b) washing said precipitate metal oxide/polymer particles until neutral in pH;
- (c) resuspending said metal oxide/polymer particles in deionized water;
- (d) stirring said metal oxide/polymer particles to break the aggregate of the metal oxide/polymer particle and;
- (e) low speed centrifugation to narrow the size distribution of said metal oxide/polymer particles.
43. The process of Claim 41 wherein the metal oxide/polymer particle is mixed with a monomer or monomers to form a metal oxide/polymer coating said monomer are selected from the group consisting of styrene, divinylbenzene, methyl methacrylate, glycidyl methacrylate, and other olefinic monomers.
44. The process of Claim 41 wherein said polymeric core particle is between 1 to 100 microns.
45. A process for the determine of presence or concentration of an analyte comprising:
- contacting magnetic particles of Claim 16 or 28;
- having a ligand specific for said analyte attached to said functionalized polymer with fluid specimen to form a suspension;
- incubating said suspension until sufficient analyte has reacted with said specific ligand;

separating said magnetic particles from said suspension;

adding a second labelled ligand specific for said analyte
to said separated magnetic particles;

5

incubating said suspension until sufficient analyte has
reacted with said second labelled ligand specific for said
analyte;

10

separating said magnetic particles from said suspension;

measuring the amount of labelled ligand associated with
said magnetic particles;

15

relating the amount of labelled ligand measured with the
amount of analyte measured for a control sample.

20

46. The process of Claim 45 wherein second ligand is labelled with
B-D-galactosidase and the amount of labelled ligand associated
with said magnetic particle is measured using the substrate
4-methylumbelliferyl-B-galactopyranoside and a fluorescence
analyzer.

25

47. The process of Claim 45 wherein the fluorescence analyzer has
about 365 nm excitation and about 450 nm emission filters.

30

48. The process of Claim 45 wherein the analyte is selected from the
group consisting of enzymes, hormones, peptides, vitamins,
nucleic acids, oligonucleotides, biological cells, antigens,
antibodies, and haptens.

49. The process of Claim 45 wherein bovine serum albumin is attached
to said functionalized polymer.

50. A process to determine the presence or concentration of specific nucleic acid sequences in nucleic acid target molecules comprising:

5 contacting magnetic particles of Claim 18 or 28 having a nucleic acid complementary to said nucleic acid sequence of said target molecule, attached to said functionalized polymer, with a fluid specimen to form a suspension;

10 incubating said suspension under hybridizing conditions for a period of time sufficient to permit hybridization;

 separating said magnetic particle from said suspension;

15 adding a second labelled nucleic acid sequence complementary to said nucleic acid sequence of said target molecule;

20 incubating said suspension under hybridizing conditions for a period of time sufficient to permit hybridization;

 separating said magnetic particle from said suspension and;

25 detecting duplex formation on said magnetic particle by means of said label.

30 51. The process of Claim 50 wherein second ligand is labelled with B-D-galactosidase and the amount of labelled ligand associated with said magnetic particle is measured using the substrate 4-methylumbelliferyl-B-galactopyranoside and a fluorescence analyzer.

52. The process of Claim 50 wherein the fluorescence analyzer has about 365 nm excitation and about 450 nm emission filters.

53. The process of Claim 50 wherein said labelled nucleic acid sequence complementary to said nucleic acid sequence of said target molecule is labelled with biotin and said label is amplified by a labelled avidin.

5

54. A process for isolating biosubstance comprising:

contacting magnetic particles of Claim 18 or 28 having a ligand specific for said biosubstance;

10

incubating said suspension until sufficient biosubstances has reacted with said ligand;

separating said magnetic particles from said suspension;

15

separating said magnetic particles from said biosubstance and;

obtaining essentially pure biosubstance.

20

55. The process of Claim 54 wherein said biosubstance are biological cells.

56. The process of Claim 54 wherein said biosubstance are proteins.

25

57. The process of Claim 54 wherein said biosubstance are bone marrow cells.

58. A process for removing unwanted biosubstance comprising:

30

contacting magnetic particles of Claim 18 or 28 having a ligand specific for said biosubstance;

incubating said suspension until sufficient biosubstances has reacted with said ligand;

id
id
is
separating said magnetic particles from said suspension and;

obtaining suspension free of unwanted biosubstance.

5 59. The process of Claim 58 wherein said biosubstance are biological cells.

60. The process of Claim 58 wherein said biosubstance are proteins.

10 61. A process for industrial waste purification comprising removing unwanted substances from industrial waste using the magnetic particles of Claim 18 or 28.

15


20

25

30

1/4

FIG. 1



2/4




FIG. II

3/4




FIG. III a

SUBSTITUTE SHEET

4 / 4




FIG. III b

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US88/03666**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4) C12Q 1/68; G01N 33/553; C02F 1/48 U.S. CL.: 252/62.51; 427/127; 436/526; 435/6; 210/695																				
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; text-align: left; padding: 5px;">Classification System</th> <th style="text-align: left; padding: 5px;">Classification Symbols</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">U.S.</td> <td style="padding: 5px;"> 210/695; 252/62.51, 62.53-62.56; 427/127-131, 212 427/214, 216, 217, 221, 222, 338, 404, 405, 407.1, 409, 414, 419, 2; 436/526, 531, 533, 534, 800, 806, 824; 435/6, 7; 935/77, 78 </td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U.S.	210/695; 252/62.51, 62.53-62.56; 427/127-131, 212 427/214, 216, 217, 221, 222, 338, 404, 405, 407.1, 409, 414, 419, 2; 436/526, 531, 533, 534, 800, 806, 824; 435/6, 7; 935/77, 78														
Classification System	Classification Symbols																			
U.S.	210/695; 252/62.51, 62.53-62.56; 427/127-131, 212 427/214, 216, 217, 221, 222, 338, 404, 405, 407.1, 409, 414, 419, 2; 436/526, 531, 533, 534, 800, 806, 824; 435/6, 7; 935/77, 78																			
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; text-align: left; padding: 5px;">Category [*]</th> <th style="text-align: left; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="text-align: left; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US, A, 3,560,378 (WEISS) 02 February 1971, see column 6, lines 31-55 and line 73 - column 7, line 33.</td> <td style="vertical-align: top; padding: 5px;">1-61</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US, A, 4,070,246 (KENNEDY) 24 January 1978, see column 2, lines 7-16, 29-32 and 51-57, column 3, lines 9-18, and 52-61.</td> <td style="vertical-align: top; padding: 5px;">1-61</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US, A, 4,177,253 (DAVIES) 04 December 1979, see Abstract, column 1, lines 32-53, column 2, lines 12-60, column 4, lines 19-45, column 5, lines 1-7 and 62-column 6, line 5, column 7, lines 57-59.</td> <td style="vertical-align: top; padding: 5px;">1-61</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US, A, 4,219,335 (EBERSOLE) 26 August 1980, see column 4, lines 5-17.</td> <td style="vertical-align: top; padding: 5px;">1-61</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US, A, 4,230,685 (SENYEI), 28 October 1980, see abstract, column 2, lines 32-60, column 3, lines 27-35</td> <td style="vertical-align: top; padding: 5px;">18-61</td> </tr> </tbody> </table>			Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	US, A, 3,560,378 (WEISS) 02 February 1971, see column 6, lines 31-55 and line 73 - column 7, line 33.	1-61	Y	US, A, 4,070,246 (KENNEDY) 24 January 1978, see column 2, lines 7-16, 29-32 and 51-57, column 3, lines 9-18, and 52-61.	1-61	Y	US, A, 4,177,253 (DAVIES) 04 December 1979, see Abstract, column 1, lines 32-53, column 2, lines 12-60, column 4, lines 19-45, column 5, lines 1-7 and 62-column 6, line 5, column 7, lines 57-59.	1-61	Y	US, A, 4,219,335 (EBERSOLE) 26 August 1980, see column 4, lines 5-17.	1-61	Y	US, A, 4,230,685 (SENYEI), 28 October 1980, see abstract, column 2, lines 32-60, column 3, lines 27-35	18-61
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																		
Y	US, A, 3,560,378 (WEISS) 02 February 1971, see column 6, lines 31-55 and line 73 - column 7, line 33.	1-61																		
Y	US, A, 4,070,246 (KENNEDY) 24 January 1978, see column 2, lines 7-16, 29-32 and 51-57, column 3, lines 9-18, and 52-61.	1-61																		
Y	US, A, 4,177,253 (DAVIES) 04 December 1979, see Abstract, column 1, lines 32-53, column 2, lines 12-60, column 4, lines 19-45, column 5, lines 1-7 and 62-column 6, line 5, column 7, lines 57-59.	1-61																		
Y	US, A, 4,219,335 (EBERSOLE) 26 August 1980, see column 4, lines 5-17.	1-61																		
Y	US, A, 4,230,685 (SENYEI), 28 October 1980, see abstract, column 2, lines 32-60, column 3, lines 27-35	18-61																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																				
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of the Actual Completion of the International Search 27 February 1989 International Searching Authority ISA/US </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of Mailing of this International Search Report: <div style="text-align: center; font-size: 1.2em; font-weight: bold;">14 APR 1989</div> Signature of Authorized Officer <div style="text-align: center;"> JACK SPIEGEL </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 27 February 1989 International Searching Authority ISA/US	Date of Mailing of this International Search Report: <div style="text-align: center; font-size: 1.2em; font-weight: bold;">14 APR 1989</div> Signature of Authorized Officer <div style="text-align: center;"> JACK SPIEGEL </div>																
Date of the Actual Completion of the International Search 27 February 1989 International Searching Authority ISA/US	Date of Mailing of this International Search Report: <div style="text-align: center; font-size: 1.2em; font-weight: bold;">14 APR 1989</div> Signature of Authorized Officer <div style="text-align: center;"> JACK SPIEGEL </div>																			

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	US, A, 4,272,510 (SMITH), 09 June 1981, see column 3, lines 50-65, and column 4, lines 29-44.	1-61
Y	US, A, 4,285,819 (YEN) 25 August 1981, see Abstract, column 1, lines 12-27, and column 4, line 64- column 5, line 3.	1-61
Y	US, A, 4,382,982 (WHILLANS) 10 May 1983, see abstract, column 1, lines 45-65, column 3, lines 27-39, and 54-66, and column 4, lines 19-30.	1-61
Y	US, A, 4,490,436 (KAWAKAMI) 25 December 1984, see Abstract column 1, lines 43-64, column 3, lines 20-27, and column 7, lines 59-62.	1-61
Y	US, A, 4,496,658 (KONDO) 29 January 1985, see column 2, lines 15-22 column 9, lines 46-65, and column 24, line 40 - column 25, line 8.	46,47, 51,52
Y	WO, A, 86/05815 (HILL) 09 October 1986, see abstract.	50-53
Y	The Lancet I, No. 8368, issued 1984 January (London), J.G. Treleaven, et al., "Removal of Neuroblastoma Cells From Marrow With Monoclonal Antibodies Conjugated To Magnetic Microspheres", pages 70-73, see Summary.	57 & 59

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

- I. Claims 1-49 drawn to magnetic particles, method of making and a ligand binding method of using same; class 436/536.
 II. Claims 50-53 drawn to a hybridization assay; class 435/6.
 III. Claims 54-61 drawn to a method of isolating or purifying; class 210/695.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. Telephone Practice

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Attachment to PCT/ISA/210
Part VI. 1.

Telephone Approval:

\$ 280 payment approved by Susan B. Fentress on 27 January 1989 for additional Groups II and III; charge to Deposit Account No. 02-1440.

Counsel advised that she has no right to protest for any group not paid for and that any protest must be filed no later than 15 days from the date of mailing of the search report. (Form 210)

Reasons for holding lack of Unity of Invention:

The invention as defined in Group I (claims 1-49), drawn to magnetic particles, method making same, and method of using same to assay the concentration of an analyte as per immunoassay which is classified in class 436, subclass 526, is a materially different process of using said magnetic particles than the invention of Group II (claims 50-53) drawn to a nucleic acid hybridization assay method classified in class 435, subclass 6, or the invention of Group III (claims 53-61) drawn to methods of isolating or purifying a substance from a liquid classified in class 210, subclass 695.

Time Limit For Filing A Protest

Applicant is hereby given 15 days from the mailing date of this Search Report in which to file a protest of the holding of lack of unity of invention. In accordance with PCT Rule 40.2 applicant may protest the holding of lack of unity only with respect to the groups(s) paid for.